Maravai’s revenue guidance for the full year 2025 is based on expectations for its existing base business and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- MRVI Upcoming Earnings Report: What to Expect?
- MRVI Lawsuit Alert! Class Action Lawsuit Against Maravai Lifesciences Holdings
- Maravai Lifesciences price target lowered to $5 from $7 at Morgan Stanley
- Maravai LifeSciences Earnings Call: Growth Amid Challenges
- Biotech Alert: Searches spiking for these stocks today